Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Haibo Shao
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07557914CT.gov Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes | — | Not Yet Recruiting | — | — | — |
NCT07475026CT.gov A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence | — | Not Yet Recruiting | — | — | — |
NCT07483359CT.gov Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus | — | Recruiting | — | — | — |
NCT07535840CT.gov A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07518706CT.gov Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin | — | Not Yet Recruiting | — | — | — |
NCT07413354CT.gov Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07480382CT.gov Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC | — | Not Yet Recruiting | — | — | — |
NCT07463248CT.gov PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy | — | Not Yet Recruiting | — | — | — |
NCT07351513CT.gov A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07363356CT.gov Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer | — | Not Yet Recruiting | — | — | — |
Show 61 more trialsShow fewer
NCT07328009CT.gov A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07363512CT.gov Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus | — | Not Yet Recruiting | — | — | — |
NCT07350070CT.gov TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension | — | Not Yet Recruiting | — | — | — |
NCT07243691CT.gov Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07077369CT.gov WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy | — | Not Yet Recruiting | — | — | — |
NCT07078305CT.gov Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment | — | Not Yet Recruiting | — | — | — |
NCT07047586CT.gov Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | — | Recruiting | — | — | — |
NCT07157969CT.gov ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | — | Recruiting | — | — | — |
NCT06602011CT.gov Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) | — | Recruiting | — | — | — |
NCT06467799CT.gov Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC | — | Recruiting | — | — | — |
NCT06530784CT.gov Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06427941CT.gov A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06420440CT.gov Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model | — | Recruiting | — | — | — |
NCT05906524CT.gov KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors | — | Unknown | — | — | — |
NCT06253598CT.gov Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06280313CT.gov Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension | — | Recruiting | — | — | — |
NCT06210334CT.gov HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) | — | Unknown | — | — | — |
NCT05910970CT.gov Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation | — | Unknown | — | — | — |
NCT06233981CT.gov Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis | — | Completed | — | — | — |
NCT05622071CT.gov Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions | — | Completed | — | — | — |
NCT05954897CT.gov Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05897138CT.gov A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | — | Not Yet Recruiting | — | — | — |
NCT06003673CT.gov A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | — | Unknown | — | — | — |
NCT05920863CT.gov Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors | — | Recruiting | — | — | — |
NCT05564338CT.gov Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT05897268CT.gov Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) | — | Unknown | — | — | — |
NCT05917431CT.gov Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | — | Recruiting | — | — | — |
NCT05807776CT.gov Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. | — | Completed | — | — | — |
NCT05675462CT.gov Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05651022CT.gov Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05545124CT.gov Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence | — | Unknown | — | — | — |
NCT05842317CT.gov Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | — | Unknown | — | — | — |
NCT05533892CT.gov Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC | — | Unknown | — | — | — |
NCT05546619CT.gov Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection | — | Unknown | — | — | — |
NCT05366829CT.gov Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05407519CT.gov A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | — | Recruiting | — | — | — |
NCT05339581CT.gov IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | — | Unknown | — | — | — |
NCT06232759CT.gov TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT05185531CT.gov A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04981665CT.gov A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | — | Unknown | — | — | — |
NCT05277675CT.gov Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study) | — | Unknown | — | — | — |
NCT05057845CT.gov Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04948697CT.gov A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | — | Completed | — | — | — |
NCT04834986CT.gov Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04850157CT.gov Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT | — | Unknown | — | — | — |
NCT04802876CT.gov Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors | — | Active Not Recruiting | — | — | — |
NCT05131698CT.gov Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT06323382CT.gov Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06333561CT.gov HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05582278CT.gov HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | — | Unknown | — | — | — |
NCT04663035CT.gov Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC | — | Unknown | — | — | — |
NCT04183088CT.gov Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04615143CT.gov Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | — | Recruiting | — | — | — |
NCT04652492CT.gov Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04599777CT.gov TACE Combined With Sorafenib and Tislelizumab for Advanced HCC | — | Completed | — | — | — |
NCT04401800CT.gov Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04996459CT.gov Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03941873CT.gov A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer | — | Completed | — | — | — |
NCT03419897CT.gov Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | — | Completed | — | — | — |
NCT04627012CT.gov Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT03412773CT.gov A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tislelizumab (this asset) | Haibo Shao | Approved | BB · 65 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Tislelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 69 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
| Classic Hodgkin Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tislelizumab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tislelizumab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →